Generic Medicine Info
Indications and Dosage
Adjunct in treatment-resistant depression
Adult: As L-tryptophan: 1 g tid. Max: 6 g daily.
Elderly: Dose reduction may be needed.
Renal Impairment
Dose reduction may be needed.
Hepatic Impairment
Dose reduction may be needed.
History of eosinophilia-myalgia syndrome associated with tryptophan treatment.
Special Precautions
May affect ability to drive or operate machinery. Monitor for suicidal thoughts or clinical worsening of depression during initial treatment period. Renal or hepatic impairment. Elderly.
Adverse Reactions
Nausea (take after food to minimise nausea), headache, lightheadedness, drowsiness, eosinophilia-myalgia syndrome.
Symptoms: Drowsiness and vomiting. Management: Treatment is supportive.
Drug Interactions
Increased risk of serotonin syndrome with SSRI. Possible decrease in levodopa plasma levels with tryptophan.
Potentially Fatal: Increased risk of severe behavioural and neurological toxicity with MAOI, start with lower initial dose of tryptophan if needed.
Description: Tryptophan is an essential amino acid which is the precursor of serotonin. It may be used as an adjunctive therapy in treatment-resistant depression. It is sometimes administered with pyridoxine and ascorbic acid. Due to its association with eosinophilia-myalgia syndrome, the use of tryptophan as dietary supplements (e.g. for insomnia) is limited or restricted.
Absorption: Readily absorbed from GI tract.
Distribution: Protein binding: Extensive, to plasma albumin.
Metabolism: By liver to metabolites e.g. hydroxytryptophan and kynurenine derivatives.
Excretion: Elimination half life (oral or IV L-tryptophan): 1-3 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Tryptophan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in